Alembic Pharmaceuticals has informed the exchange that the Company has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Bioequivalence Facility located at Vadodara without any observations. The inspection was conducted from 17th October, 2022 to 21st October, 2022.
The above information is a part of company’s filings submitted to BSE.